Assessment of the HER2, PDL1 and oxidative stress levels at the menopausal status of newly diagnosed breast cancer patients


  • Baraa R. Mahmood Biochemistry laboratory, Ibn Al Atheer Children's Hospital, Ministry of Health, Mosul, Iraq.
  • Thikra A. Allwsh Department of Chemistry, College of Science, University of Mosul, Mosul, Iraq.



Breast Neoplasms, Epidermal Growth Factor, Oxidative Stress


Objective: This study aimed to estimate the levels of HER2, PD-L1 and oxidative stress in newly diagnosed breast cancer patients. Also, to estimate the probability of using HER2 and PD-L1 as a predictive marker on the occurrence of breast cancer in addition to study the effect of menopausal status at the level of HER2, PD-L1, oxidative stress and breast cancer risk factor.

Methods: This study included 125 newly diagnosed breast cancer patients (53 premenopausal and 72 postmenopausal) from Oncology and Nuclear Medicine Hospital in Mosul, Iraq, and 100 apparently healthy women as a control group (44 premenopausal and 56 postmenopausal), during the period from Jan. 2021 to Jun. 2021. The ages of patients and control are matched, and it is ranged from 30-60 years.

In this study we estimate the level of Human Epidermal Growth Factor Receptor 2 (HER2), Programmed Death -Ligand 1(PD-L1), total antioxidant capacity (T-AOC), arylesterase activity, uric acid level, malondialdehyde (MDA) level, peroxidase activity, lactoperoxidase activity and iron level at breast cancer patients and control.

Results: The results show that there is a significant elevation in the level of HER2, PD-L1, malondialdehyde, peroxidase, lactoperoxidase and iron, and a significant decrease in the level of T-AOC, arylesterase and uric acid in the serum of breast cancer patients (pre and postmenopausal) compared with the control group (pre and postmenopausal).

 Also, increase the level of HER2 and oxidative stress at postmenopausal status for the control and patient groups. while PD-L1 level does not affect by menopausal status for both control and patient groups.

Conclusion: The level of HER2, PD-L1, and oxidative stress was significantly increased in newly diagnosed breast cancer patients compared with the control group at the same menopausal status.  Increase breast cancer risk factor at the postmenopausal status.


Sadoughi F, Kazemy Z, Hamedan F, Owji L, Rahmanikatigari M, Azadboni TT. Artificial intelligence methods for the diagnosis of breast cancer by image processing: a review. Breast Cancer (Dove Med Press). 2018;10:219-230. doi:10.2147/BCTT.S175311

Mendoza L. Potential effect of probiotics in the treatment of breast cancer. Oncol Rev. 2019;13(2):422. doi:10.4081/oncol.2019.422

Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Med Press). 2019;10;11:151-164. doi: 10.2147/BCTT.S176070.

Mhmood, B., Allwsh, T. Study of HER2 in Breast Cancer Disease. Egyptian Journal of Chemistry, 2021; 64(12): 7107-7112. doi: 10.21608/ejchem.2021.80147.3955

Aisyah S, Handharyani E, Bermawie N, Setiyono A. Effects of ethanol extract of curry leaves (Murraya koenigii) on HER2 and caspase-3 expression in rat model mammary carcinoma. Vet World. 2021;14(8):1988-1994. doi: 10.14202

Shukla S, Singh BK, Pathania OP, Jain M. Evaluation of HER2/neu oncoprotein in serum & tissue samples of women with breast cancer. Indian J Med Res. 2016;143:S52-S58. doi: 10.4103/0971-5916.191769.

Muhammad IF, Borné Y, Bao X, Melander O, Orho-Melander M, Nilsson PM, Nilsson J, Engström G. Circulating HER2/ErbB2 Levels Are Associated With Increased Incidence of Diabetes: A Population-Based Cohort Study. Diabetes Care. 2019 Aug;42(8):1582-1588. doi: 10.2337/dc18-2556.

Xiaolin Sang, Li Li, Chunhua Rui, Yichao Liu, Zundong Liu, Zhiwei Tao, Hailing Cheng, Pixu Liu, Induction of EnR stress by Melatonin enhances the cytotoxic effect of Lapatinib in HER2-positive breast cancer, Cancer Letters, 2021; 518: 82-93, ISSN 0304-3835,

Serova OV, Chachina NA, Gantsova EA, Popova NV, Petrenko AG, Deyev IE. Autophosphorylation of Orphan Receptor ERBB2 Can Be Induced by Extracellular Treatment with Mildly Alkaline Media. Int J Mol Sci. 2019;20(6):1515. doi: 10.3390/ijms20061515.

Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Kofler M, Jorissen RN, Nice EC, Burgess AW, Ward CW. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell. 2003;11(2):495-505. doi: 10.1016/s1097-2765(03)00048-0.

Oganesyan V, Peng L, Bee JS, Li J, Perry SR, Comer F, Xu L, Cook K, Senthil K, Clarke L, Rosenthal K, Gao C, Damschroder M, Wu H, Dall'Acqua W. Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody. J Biol Chem. 2018;293(22):8439-8448. doi: 10.1074/jbc.M117.818013..

Leech AO, Vellanki SH, Rutherford EJ, Keogh A, Jahns H, Hudson L, O'Donovan N, Sabri S, Abdulkarim B, Sheehan KM, Kay EW, Young LS, Hill ADK, Smith YE, Hopkins AM. Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings. Breast Cancer Res. 2018;20(1):140. doi: 10.1186/s13058-018-1064-1.

Barros FF, Powe DG, Ellis IO, Green AR. Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments. Histopathology. 2010;56(5):560-72. doi: 10.1111/j.1365-2559.2010.03494.x.

Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727-742.

Nascimento, C., Urbano, A. C., Gameiro, A., Ferreira, J., Correia, J., & Ferreira, F. (2020). Serum PD-1/PD-L1 Levels, Tumor Expression and PD-L1 Somatic Mutations in HER2-Positive and Triple Negative Normal-Like Feline Mammary Carcinoma Subtypes. Cancers, 12(6), 1386.

Schütz F, Stefanovic S, Mayer L, von Au A, Domschke C, Sohn C. PD-1/PD-L1 Pathway in Breast Cancer. Oncol Res Treat. 2017;40(5):294–297. Available from:

Kim, A.; Lee, S.J.; Kim, Y.K.; Park, W.Y.; Park, D.Y.; Kim, J.Y.; Lee, C.H.; Gong, G.; Huh, G.Y.; Choi, K.U. Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value. Sci. Rep. 2017, 7, 11671.

Pizzino G, Irrera N, Cucinotta M, Pallio G, Mannino F, Arcoraci V, Squadrito F, Altavilla D, Bitto A. Oxidative Stress: Harms and Benefits for Human Health. Oxid Med Cell Longev. 2017;2017:8416763. doi: 10.1155/2017/8416763.

Sukumar J, Gast K, Quiroga D, Lustberg M, Williams N. Triple-negative breast cancer: promising prognostic biomarkers currently in development. Expert Rev Anticancer Ther. 2021;21(2):135-148. doi: 10.1080/14737140.2021.1840984.

Wu JQ, Kosten TR, Zhang XY. Free radicals, antioxidant defense systems, and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2013 1;46:200-6. doi: 10.1016/j.pnpbp.2013.02.015.

Didžiapetrienė J, Kazbarienė B, Tikuišis R, Dulskas A, Dabkevičienė D, Lukosevičienė V, Kontrimavičiūtė E, Sužiedėlis K, Ostapenko V. Oxidant/Antioxidant Status of Breast Cancer Patients in Pre- and Post-Operative Periods. Medicina. 2020; 56(2):70.

Haque T, Rahman s, Islam S, Molla NH, Ali N. Assessment of the relationship between serum uric acid and glucose levels in healthy, prediabetic and diabetic individual. Diabetology & metabolic syndrome.2019;11:49

Pellegrini N, Serafini M, Salvatore S, Del Rio D, Bianchi M, Brighenti F. Total antioxidant capacity of spices, dried fruits, nuts, pulses, cereals and sweets consumed in Italy assessed by three different in vitro assays. Mol Nutr Food Res. 2006;50(11):1030-8. doi: 10.1002/mnfr.200600067.

Jasim R and Allwsh T. Study of arylesterase and its relationship with some clinical variables in atherosclerotic patients in Mousl (part 1). Rafidain jurnal of science. 2008;19(2):143-157

Jasim R, Mohamaad S and Allwsh T. The Relation between Fibroblast Growth Factor 21 and Insulin Resistance in hyperlipidemia Patients. Egypt. J. Chem. 2021; 64(12): 7091-7094

Guidet, B.; Shah, S. V. Enhanced in vivo H2O2 generation by rat kidney in glycerol-induced renal failure. American Journal of Physiology-Renal Physiology. 1989; 257(3): 440–445. doi:10.1152/ajprenal.1989.257.3.f440

Nelson J and Kulkarni A. Partial purification and characterization of a peroxidase activity from human placenta. Biochemical Journal. 1990; 268(3): 739-743.

Tayefi-Nasrabadi H, Hosseinpour-fiezi M, Mohasseli M. Thermodynamic analysis of lactoperoxidase activity in camel milk. International Conference on Life Science and Technology. IPCBEE- Singapore.2011;3:4-6

Douglas J, Gary R, Frank E, and Stephen L. Ferene — a new spectrophotometric reagent for iron. Canadian Journal of Chemistry.1984;62(4):721-724.

Tietz N. Textbook of clinical chemistry,3 ed Ed. C. A. Burtis, E. R. Ashwood, W. B. Saunders. 1999: 1245-1250.

Banys-Paluchowski M, Witzel I, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer EF, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T, Müller V. Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients. Anticancer Res. 2017;37(6):3117-3128. doi: 10.21873/anticanres.11669.

Fabricio ASC, Michilin S, Zancan M, Agnolon V, Peloso L, Dittadi R, Scapinello A, Ceccarelli C, Gion M. Shed HER2 surrogacy evaluation in primary breast cancer patients: a study assessing tumor tissue HER2 expression at both extracellular and intracellular levels. Scand J Clin Lab Invest. 2019;79(4):260-267. doi: 10.1080/00365513.2019.1600200.

Lam L, McAndrew N, Yee M, Fu T, Tchou JC, Zhang H. Challenges in the clinical utility of the serum test for HER2 ECD. Biochim Biophys Acta. 2012;1826(1):199-208. doi: 10.1016/j.bbcan.2012.03.012.

Di Gioia D, Dresse M, Mayr D, Nagel D, Heinemann V, Stieber P. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer. Clin Chim Acta. 2015;440:16-22. doi:10.1016/j.cca.2014.11.001Higher

Bashamakha G, Bin Sumait H, Bashamakha M, Al Serouri A, Khader Y. Risk Factors of Breast Cancer in Hadramout Valley and Desert, Yemen. Int J Prev Med. 2019; 10:161. doi: 10.4103/ijpvm.IJPVM_251_17.

Qui S, Takeshita T, Sueta A, Tomiguchi M, Goto-Yamaguchi L, Hidaka K, Suzu I, Yamamoto Y, Iwase H. Analysis of plasma HER2 copy number in cell-free DNA of breast cancer patients: a comparison with HER2 extracellular domain protein level in serum. Breast Cancer. 2021;28(3):746-754. doi: 10.1007/s12282-020-01212-x.

Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, de Boer M, Borm GF, Tjan-Heijnen VC. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat.2013; 141(3): (507-14). doi: 10.1007/s10549-013-2711-y

Nascimento C, Urbano AC, Gameiro A, Ferreira J, Correia J, Ferreira F. Serum PD-1/PD-L1 Levels, Tumor Expression and PD-L1 Somatic Mutations in HER2-Positive and Triple Negative Normal-Like Feline Mammary Carcinoma Subtypes. Cancers (Basel). 2020;12(6):1386. doi:10.3390/cancers12061386

Lawler SE, Nowicki MO, Ricklefs FL, Chiocca EA. Immune Escape Mediated by Exosomal PD-L1 in Cancer. Adv Biosyst. 2020;4(12):e2000017. doi:10.1002/adbi.202000017

Salama EA, Adbeltawab RE, El Tayebi HM. XIST and TSIX: Novel Cancer Immune Biomarkers in PD-L1-Overexpressing Breast Cancer Patients. Front Oncol. 2020;9:1459. doi:10.3389/fonc.2019.01459

Han B, Dong L, Zhou J, Yang Y, Guo J, Xuan Q, Gao K, Xu Z, Lei W, Wang J, Zhang Q. The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte. Cancer Immunol Immunother. 2021;70(10):2893-2909. doi: 10.1007/s00262-021-02898-4.

Sultana DR, Shahin AD, Md Jawadul H. Measurement of oxidative stress and total antioxidant capacity in hyperthyroid patients following treatment with carbimazole and antioxidant. Heliyon. 2021; 8(1):e08651. doi: 10.1016/j.heliyon.2021.e08651.

Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked?. Free Radic Biol Med. 2010;49(11):1603-1616. doi:10.1016/j.freeradbiomed.2010.09.006

Okuturlar Y, Gunaldi M, Kocoglu H, Hursitoglu1 M, Gedikbasi A, Didem Acarer D, Harmankaya O, Kumbasar A. Serum paraoxonase and arylesterase can be useful markers to predict neoadjuvant chemotherapy requirement in patients with breast cancer. J Cancer Res Ther. 2018;14(9):362-367. doi:10.4103/0973-1482.235355

Bourgonje AR, Abdulle AE, Al-Rawas AM, Al-Maqbali M, Al-Saleh M, Enriquez MB, Al-Siyabi S, Al-Hashmi K, Al-Lawati I, Bulthuis MLC, Mulder DJ, Gordijn SJ, van Goor H, Saleh J. Systemic Oxidative Stress Is Increased in Postmenopausal Women and Independently Associates with Homocysteine Levels. Int J Mol Sci. 2020;21(1):314. doi: 10.3390/ijms21010314.

Galaris D, Barbouti A, Pantopoulos K. Iron homeostasis and oxidative stress: An intimate relationship. Biochim Biophys Acta Mol Cell Res. 2019 Dec;1866(12):118535. doi: 10.1016/j.bbamcr.2019.118535.

Kangari P, Zarnoosheh Farahany T, Golchin A, Ebadollahzadeh S, Salmaninejad A, Mahboob SA, Nourazarian A. Enzymatic Antioxidant and Lipid Peroxidation Evaluation in the Newly Diagnosed Breast Cancer Patients in Iran. Asian Pac J Cancer Prev. 2018;19(12):3511-3515. doi: 10.31557/APJCP.2018.19.12.3511.

Sarmiento-Salinas FL, Delgado-Magallón A, Montes-Alvarado JB, Ramírez-Ramírez D, Flores-Alonso JC, Cortés-Hernández P, Reyes-Leyva J, Herrera-Camacho I, Anaya-Ruiz M, Pelayo R, Millán-Pérez-Peña L, Maycotte P. Breast Cancer Subtypes Present a Differential Production of Reactive Oxygen Species (ROS) and Susceptibility to Antioxidant Treatment. Front Oncol. 2019 Jun 7;9:480. doi: 10.3389/fonc.2019.00480.

Priyanka HP, Nair RS. Neuroimmunomodulation by estrogen in health and disease. AIMS Neurosci. 2020;7(4):401-417. doi:10.3934/Neuroscience.2020025




How to Cite

Mahmood, B. R. ., & Allwsh, T. A. . (2022). Assessment of the HER2, PDL1 and oxidative stress levels at the menopausal status of newly diagnosed breast cancer patients. Journal of Contemporary Medical Sciences, 8(5), 352–356.